Dermatol. praxi. 2021;15(2):78-82 | DOI: 10.36290/der.2021.015
Current options of non-surgical treatment of melanoma in practice
- Dermatovenerologická klinika 1. LF UK a VFN, Praha
Melanoma is the most malignant skin cancer known for its high mortality rate and delayed formation of metastases. The treatment of metastatic melanoma is currently going through a golden age since novel drugs from the classes of immunotherapeutics and targeted agents are becoming available on the market. These drugs significantly increase the rate of induced remissions and prolong overall survival. The mechanism of action of immunotherapeutic drugs is based on blocking of inhibitory immune checkpoints in order to increase the efficacy of the body's own immune system against tumour cells. As more modern agents are being introduced into the market, a positive trend in the treatment of metastatic melanoma will certainly continue. The article presents an overview of the treatment of early- and late-stage melanomas, taking into account the modern non-surgical systemic therapy for metastatic melanoma as well as its use in adjuvant therapy. Also discussed are the most frequent adverse effects of systemic treatment.
Keywords: melanoma, immunotherapy, targeted therapy, adverse effect, adjuvant therapy.
Published: September 2, 2021 Show citation
References
- Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017; 376(23): 2211-2222.
Go to original source... 
Go to PubMed... - Ma Y, Wang Q, Dong Q, et al. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019; 9(8): 1546-1553.
- Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016; 62: 132-137. Go to original source... Go to PubMed...
- Puzanov I, Diab A, Abdallah K, et al. Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5(1): 95. Go to original source... Go to PubMed...
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019; 381(16): 1535-1546. Go to original source... Go to PubMed...
- Krajsová I, Bauer J. Melanom - imunoterapie a cílená léčba. 1. vydání. Praha: Maxdorf, 2017: 382 s.
- Mocellin S, Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013; (6): CD008955. Go to original source...
- Thomas D, Bello DM. Adjuvant immunotherapy for melanoma. J Surg Oncol. 2021; 123: 789-797. Go to original source... Go to PubMed...